Osimertinib Could Change Standard of Care for EGFR-Mutated NSCLC
ML Fuerst - 2024 - journals.lww.com
By MArK L. FUerst received definitive platinum-based chemoradiotherapy. Patients were
randomly assigned to receive osimertinib (143 patients) or a placebo (73 patients). Median …
randomly assigned to receive osimertinib (143 patients) or a placebo (73 patients). Median …
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
S Lu, T Kato, X Dong, MJ Ahn, LV Quang… - … England Journal of …, 2024 - Mass Medical Soc
Background Osimertinib is a recommended treatment for advanced non–small-cell lung
cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation and as adjuvant …
cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation and as adjuvant …
[HTML][HTML] Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
D Planchard, PA Jänne, Y Cheng… - … England Journal of …, 2023 - Mass Medical Soc
Background Osimertinib is a third-generation epidermal growth factor receptor–tyrosine
kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …
kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …
Upfront osimertinib—winner takes it all?
The survival outcomes of the FLAURA trial support osimertinib as the new first-line standard
of care for patients with EGFR-mutated advanced-stage non-small-cell lung cancer in health …
of care for patients with EGFR-mutated advanced-stage non-small-cell lung cancer in health …
A real-world study of patient characteristics and clinical outcomes in EGFR-mutated lung cancer treated with first-line osimertinib.
H Viray, A Piper-Vallillo, P Widick, E Academia, M Shea… - 2022 - ascopubs.org
e21033 Background: Osimertinib is a third-generation mutation-specific covalent tyrosine
kinase inhibitor of epidermal growth factor receptor (EGFR) that is used for first-line therapy …
kinase inhibitor of epidermal growth factor receptor (EGFR) that is used for first-line therapy …
[HTML][HTML] Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
JC Soria, Y Ohe, J Vansteenkiste… - New England journal …, 2018 - Mass Medical Soc
Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
A phase II study to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC who developed isolated CNS progression (T790M-negative or …
M Takeda, M Shimokawa, A Nakamura, K Nosaki… - Clinical Lung Cancer, 2021 - Elsevier
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI) that has recently been established as a standard treatment option for …
inhibitor (TKI) that has recently been established as a standard treatment option for …
Corrigendum to “A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation–positive NSCLC in whom systemic disease …
M Takeda, M Shimokawa, A Nakamura… - Lung …, 2024 - lungcancerjournal.info
The authors regret, the content of a part of Results and Figs. 3A and B is incorrect in the
current version published online. I will revise the current incorrect Results and Figures to the …
current version published online. I will revise the current incorrect Results and Figures to the …
[HTML][HTML] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
SS Ramalingam, J Vansteenkiste… - … England Journal of …, 2020 - Mass Medical Soc
Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI …
Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study
Y Cheng, Y He, W Li, H Zhang, Q Zhou, B Wang… - Targeted Oncology, 2021 - Springer
Background In the global FLAURA study, first-line osimertinib, a third-generation irreversible
tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), significantly …
tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), significantly …